Provides comprehensive oncology services across the United States. Offers in-house laboratory services for routine and specialized testing. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 25% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 0.2× for every dollar of annual revenue.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 62% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 25% a year on average.
The company sells $1.8B a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 14 buys and 5 sells. Management buying with its own money is usually read as a good sign.
A loss of $4.0M against $1.8B in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back.
As the slice kept from each sale thins out, so does the profit.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.